[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.179.146. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
September 5, 2012

Antiplatelet Therapy Following Myocardial Infarction in Patients With Diabetes

Author Affiliations

Author Affiliations: VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

JAMA. 2012;308(9):921-922. doi:10.1001/2012.jama.11467

Despite advances in the care of patients with diabetes with myocardial infarction (MI), recurrent ischemic events remain common.1 Although many explanations exist for this excess risk among patients with vs those without diabetes, one mechanism appears to be heightened platelet reactivity. It seems logical that antiplatelet therapy would be of benefit in diabetes or that more potent antiplatelet therapy would be required in diabetes.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×